AstraZeneca has launched AstraZeneca Direct, a new online service designed to help eligible patients in the US get their prescribed medications at clear cash prices with the convenience of home delivery. This platform is aimed at supporting people with chronic conditions like asthma, diabetes, heart failure, and chronic kidney disease, as well as those seeking flu protection. Starting October 1, 2025, patients with prescriptions for AIRSUPRA (albuterol/budesonide) or FARXIGA (dapagliflozin) can purchase these medications directly through AstraZeneca Direct at discounts of up to 70% off the list price. The platform also offers FLUMIST, a live influenza vaccine given through the nose, which is available for home delivery.
Health Technology Insights: Leo Cancer Care Raises $40 Million to Grow Upright Radiotherapy
Joris Silon, the US Country President of AstraZeneca, said the company is committed to making healthcare more accessible and affordable while continuing to drive innovation. He highlighted that AstraZeneca Direct provides patients with a simple way to buy their medications and the added convenience of having them delivered right to their home. Silon mentioned that this new service complements the company’s existing patient support programs and represents an important step forward in helping patients get the treatments they need quickly and easily. He also stressed AstraZeneca’s ongoing commitment to improving patient experiences and outcomes through initiatives like this platform.
Health Technology Insights: Prescryptive Earns HITRUST Certification for Data Security
AstraZeneca Direct continues the company’s long-standing patient assistance programs in the US, which remain unchanged for eligible individuals. These programs have helped many patients access AstraZeneca medicines at reduced prices or for free, based on their eligibility. Patients can start using AstraZeneca Direct by visiting AstraZenecaDirect.com beginning on October 1, 2025. The online platform aims to reduce barriers to medication access by offering an affordable and dependable option beyond traditional pharmacy channels.
Regarding AIRSUPRA, AstraZeneca provides essential safety information. Patients should not use AIRSUPRA if they are allergic to any of its ingredients and must inform their healthcare providers about their medical history and current medications before starting treatment. The recommended dose is two inhalations as needed, with a maximum of 12 puffs in 24 hours. AIRSUPRA is not meant for long-term asthma control and should not replace existing asthma medications without consulting a healthcare provider. The medication carries risks such as worsening breathing difficulties, heart problems, allergic reactions, and changes in blood chemistry. Patients should seek immediate medical help if they experience serious side effects or if the medication does not provide relief.
AIRSUPRA is a combination of two medicines and is approved for adults 18 years and older as a rescue inhaler to treat or prevent asthma symptoms and help avoid sudden severe asthma attacks. Common side effects include headache, cough, and hoarseness, but patients should consult their healthcare provider for full information on the potential risks and benefits. AstraZeneca Direct helps make these important medications more accessible, giving patients greater ease and peace of mind in managing their chronic conditions.
Health Technology Insights: Net Health to Build Largest Patient Outcomes Platform for Rehab Therapy Providers
To participate in our interviews, please write to our HealthTech Media Room at sudipto@intentamplify.com
